Regulatory Information
BAYER (SOUTH EAST ASIA) PTE LTD
BAYER (SOUTH EAST ASIA) PTE LTD
Therapeutic
Pharmacy Only
Formulation Information
TABLET, SUGAR COATED
**Dosage and Administration** Adults and Children 12 years of age and over: One Clarityn-D® 24 Hour Extended Release Tablet once daily. Clarityn-D® 24 Hour Extended Release may be taken without regard to meal time. Patients who have a history of difficulty in swallowing tablets or who have known upper gastrointestinal narrowing or abnormal esophageal peristalsis should not use this product (see Precautions and Adverse Reactions – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
ORAL
Medical Information
**Indications and usage** Clarityn-D® 24 Hour Extended Release is indicated for the relief of symptoms associated with allergic rhinitis and the common cold, including nasal congestion, sneezing, rhinorrhea, pruritus and lacrimation. Clarityn-D® 24 Hour Extended Release is recommended when both the antihistaminic properties of loratadine and the decongestant effect of pseudoephedrine sulfate are desired.
**Contraindications** Clarityn-D® 24 Hour Extended Release Tablets are contraindicated in those who have shown sensitivity or idiosyncrasy to their components or to adrenergic agents. Clarityn-D® 24 Hour Extended Release Tablets also are contraindicated in patients receiving MAO inhibitor therapy or within two weeks of discontinuing such treatment and in patients with narrow angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease and hyperthyroidism.
R01BA52
pseudoephedrine, combinations
Manufacturer Information
BAYER (SOUTH EAST ASIA) PTE LTD
SAG Manufacturing S.L.U.
Active Ingredients
Documents
Patient Information Leaflets
Clarityn-D 24h PIL & PI.pdf
Approved: September 23, 2022